ASCO Gastric Cancer Information

ASCO Gastric Cancer Information

• February 12, 2016
• Reading time: 1 minute

ASCO's study on whether Opdivo is effective and safe for gastric cancer. This publication presents research data from administering Opdivo to patients with advanced gastric cancer. It suggests that Opdivo may be effective and safe for advanced gastric and gastroesophageal junction (GEJ) cancers. The trial is currently ongoing.

The findings are summarized as follows:

• Objective response rate (ORR, tumor shrinkage by a certain percentage) was 14% (8/56). One patient achieved a Complete Response (CR).
• Disease control rate (DCR, percentage of patients with shrinkage + stable disease) was 32%.
• The median time to response was 1.6 months (range: 1.2–4 months).
• Median overall survival (OS) was 5 months, with a 6-month survival rate of 49% and a 1-year survival rate of 36%.
• Patients with PD-L1 expression showed a better response.

Participant Information: The average age was 60 (range: 29–80), 95% were Caucasian (56 people), and 5% were Black (3 people). Esophageal cancer accounted for 15% (9 people), gastroesophageal junction cancer for 53% (31 people), and gastric cancer for 31% (18 people). Over half (58%) had received at least four prior lines of treatment.

This article was summarized and translated by Medical Supporter for reference only. For detailed content, please refer to the official ASCO release.

Please refer to the following URL for the full article: http://meetinglibrary.asco.org/content/160127-173

Gastric Cancer

• Key Discoveries in the Highly Aggressive Nature of Pancreatic Cancer
• New Immunopotentiators Support Cancer Immunotherapy
• Kyoto University Launches iPS Cell Cancer Treatment!

Medical Supporter Formerly certified by Japan's Ministry of Foreign Affairs and METI as an international medical visa guarantor (B-066).

Figure 1

Figure 2

Figure 3

Figure 4